Events
It is predicted that more than 2 million new cancer diagnoses will be made in 2026, with over 600,000 cancer-related deaths in the United States alone. The pharmaceutical industry has responded with the development of new oncology modalities, particularly in the conjugations space.
The annual growth of antibody drug conjugates (ADC) has increased by approximately twenty-five percent annually since 2020. ADCs were developed to be a “magic bullet” that only targeted cancer cells, but the reality of ADC therapies is drug resistance, premature payload leakage, off target toxicity and organ damage. Emerging from these known liabilities are a next generation of ADCs. These ADCs have changes such as dual payloads and bispecific antibodies with the goal of increasing the potency of the warhead but minimizing the toxic side effects. Dual payloads target two different mechanisms for cell survival (e.g. DNA Topoisomerase I Inhibitors and Tubulin/Microtubule Inhibitors) and are being developed to counter payload resistance in the cells.
A shift from monoclonal antibodies to bispecific antibodies is trending in order to bind two different epitopes or antigens simultaneously increasing the chances of on target binding. Research is underway for other conjugate modalities such as degrader antibody conjugates, oligonucleotide antibody conjugates and peptide antibody conjugates as oncology therapies. The bioanalysis of ADCs requires complex assays to deliver quality data for regulatory submission.
Presented by Chad Christianson, Analytical Development Manager
Moderated by Leslie Hvozda, Senior Scientist
Wednesday, December, 2026
1:15 PM ET
"*" indicates required fields